Evidence map›Paper›PMID 41550652›Full record

ArticlePharmaceutical science advances2025

Comprehensive multi-omics analysis of CD36 in pan-cancers: Evaluating role in prognosis, immune microenvironment, and therapeutic response.

Muhammad Sameer Ashaq, Shengsong Wang, Meiqi Guo, Lingling Wang, Zhuoran Li, Yi Wang, Yufeng Huang, Yuan Li, Baobing Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutical science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Muhammad Sameer AshaqState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
Shengsong WangShandong Center for Food and Drug Evaluation & Inspection, Jinan, Shandong, 250013, China.
Meiqi GuoState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
Lingling WangState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
Zhuoran LiState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
Yi WangState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
Yufeng HuangState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
Yuan LiState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
Baobing ZhaoState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cluster of differentiation-36 (CD36) is involved in cellular adhesion, lipid metabolism, immunity, and inflammation. Multiple studies have enlightened the regulatory roles of CD36 in metabolic reprogramming, metastasis, chemoresistance, stemness, immune modulation, senescence, inflammation, and angiogenesis. However, its role in tumorigenesis is still unclear and context-dependent. We performed a comprehensive pan-cancer analysis of CD36 by using data from TCGA, integrating transcriptomic, proteomic, methylation, mutational, immune infiltration, immunotherapy, and drug sensitivity datasets. Expression patterns, clinical associations, prognostic potential, immune interactions, and therapeutic implications were systematically evaluated. We also evaluated CD36-related molecular pathways and immune signatures in cancer by a comprehensive GSEA analysis. We found that CD36 expression pattern is dysregulated in multiple cancer types, whereas higher expression correlated with poor prognosis in LGG, BRCA, CESC, and LAML.

Indexed as

CD36Drug sensitivityImmune microenvironmentImmunotherapyPan-cancerPrognosis

Identifiers

PMID41550652
PMCPMC12709870

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.